Shigellosis

Journal of Microbiology

Volumn 43, Issue 2, 2005, Pages 133-143

  Niyogi, Swapan Kumar ^a  

^a NATIONAL INSTITUTE OF CHOLERA AND ENTERIC DISEASES   (India)

Author keywords

Drug resistance; Dysentery; Laboratory diagnosis; Pathogenesis; Serotypes; Shigellosis; Treatment; Vaccine

Indexed keywords

AMPICILLIN; ANTIINFECTIVE AGENT; AZITHROMYCIN; BACTERIAL TOXIN; CEFIXIME; CEFTRIAXONE; CEPHALOSPORIN; CIPROFLOXACIN; COTRIMOXAZOLE; INACTIVATED VACCINE; LEVOFLOXACIN; LIPOPOLYSACCHARIDE; LIVE VACCINE; MECILLINAM; NALIDIXIC ACID; NORFLOXACIN; QUINOLINE DERIVED ANTIINFECTIVE AGENT; RIFAXIMIN; SHIGA TOXIN; SHIGELLA VACCINE; SULFONAMIDE; TETRACYCLINE; VIRULENCE FACTOR;

ABDOMINAL CRAMP; ANTIBIOTIC RESISTANCE; BACTERIAL TRANSMISSION; BACTERIAL VIRULENCE; BRAIN DISEASE; CELL DEATH; CHONDROPATHY; CLINICAL TRIAL; COLITIS; COLON HEMORRHAGE; COLON ULCER; CYTOTOXICITY; DEHYDRATION; DIARRHEA; DISEASE SEVERITY; DRUG EFFICACY; DRUG SAFETY; DYSENTERY; FECES ANALYSIS; FECES CULTURE; FOOD CONTAMINATION; HUMAN; IMMUNITY; IMMUNOLOGY; INTESTINE FLORA; INTESTINE PERFORATION; MORBIDITY; MORTALITY; NEUROTOXICITY; PATHOGENESIS; PATHOGENICITY; REHYDRATION; REVIEW; SEIZURE; SEROTYPE; SHIGELLA; SHIGELLA BOYDII; SHIGELLA DYSENTERIAE; SHIGELLA FLEXNERI; SHIGELLA SONNEI; SHIGELLOSIS; WATER CONTAMINATION;

DRUG RESISTANCE, BACTERIAL; DYSENTERY, BACILLARY; HUMANS; SHIGELLA; SHIGELLA VACCINES; VIRULENCE FACTORS;

SHIGELLA BOYDII; SHIGELLA DYSENTERIAE; SHIGELLA FLEXNERI; SHIGELLA SONNEI;

EID: 19344366789     PISSN: 12258873     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (115)

1. Acheson, D.W.K., A. Donohue-Rolfe, and G.T. Keusch. 1991. The family of Shiga and Shiga-like toxins. p. 415-433. In J E Alouf and J H Freer (ed.), Sourcebook of Bacterial Protein Toxins. Academic Press, New York.
2. Ackerman, B.H and F.A Dello Buono. 1996. In vitro testing of antibiotics. Pharmacotherapy 16, 201-221.
3. Angulo, F.J. and D.L. Swerdlow. 1995. Bacterial enteric infections in persons infected with human immunodeficiency virus. Clin. Inf. Dis. 21 Suppl. 1, S84-S93.
4. Ashkenazi, S., G. Dinari, A. Zevulunov, and M. Nitzan. 1987. Convulsions in childhood shigellosis. Clinical and laboratory features in 153 children. Am. J. Dis. Child 141, 208-210.
5. Ashkenazi, S, J. Amir, Y. Waisman, A. Rachmel, B.Z. Garty, Z. Samra, I. varsano, and M.M. Nitzan. 1993. A randomized, double-blind study compairing cefixime and trimethoprim-sulpha-methoxazole in the treatment of childhood shigellosis. J. Paediatr. 123, 817-821.
6. Ashkenazi, S., J.H. Passwell, E. Harlev, D. Miron, R. Dagan, N. Farzan, R. Ramon, F. Majady, D.A. Bryla, A.B. Karpas, J.B. Robbins, and R. Schneerson. The Israel Paediatric Shigella Study Group. 1999. Safety and immunogenecity of Shigella sonnei and Shigella flexneri 2a O specific polysaccharide conjugates in children. J. Infect. Dis. 179, 1565-1568.
7. Basualdo, W., and A. Arbo. 2003. Randomized comparison of azithromycin versus cefixime for treatment of shigellosis in children. Pediatr. Infect. Dis. J. 22(4), 347-377.
8. Batchelor, B.I, J.N. Kimari, and R.J. Brindle. 1996. Microbiology of HIV associated bacteraemia and diarrhoea in adults from Nairobi, Kenya. Epidemiol. Infect. 117, 139-144.
9. Behring. E. and S. Kitasato. 1890. Ueber das Zustandkommen der Diphtherie-Immunitaet und der Tetanus-Immunitaet bei Thieren. Dtsch. Med. Wochenschr. 49, 1-6
10. Bennish, M.L., MA. Salam, R. Haider, and M. Barza 1990. Therapy for Shigellosis. II. Randomized,double-blind comparison of ciprofloxacin and ampicillin. J. Infect. Dis. 162, 711-716.
11. Bennish, M.L. 1991. Potentially lethal complications of shigellosis. Rev. Infect. Dis. 13(Suppl. 4), S319-324.
12. Bennish, M.L., and B.J. Wojtyniak. 1991. Mortality due to shigellosis: community and hospital data. Rev. Infect. Dis. 13(Suppl. 4), S245-251.
13. Bergey's manual of Determinative Bacteriology. 3rd ed. Williams & Wilkins Co., Baltimore, Maryland 1930: 357-363.
14. Berlutti, F., M. Casalino, C. Zagaglia, P.A. Frandiani, P. Visca, and M. Nicoletti. 1998. Expression of the virulence plasmid-carried apyrase gene (apy) of enteroinvasive Escherichia coli and Shigella flexneri is under the control of H-NS and the VirF and VirB regulatory cascade. Infect. Immun. 66, 4957-4964.
15. Bhattacharya, M.K., G.B. Nair, D. Sen, M. Paul, A. Debnath, A. Nag, D. Dutta, P. Dutta, S.C. Pal, and S.K. Bhattacharya. 1992. Efficacy of norfloxacin for shigellosis: A double-blind randomized clinical trial. J. Diarrhoeal. Dis. Res. 10, 146-150.
16. Bhattacharya, S.K., P. Dutta, D. Dutta, M.K. Bhattacharya, D. Sen, M.R. Saha, G.B. Nair, P. Das, S.N. Sikdar, R. Bose, and S.C. Pal. 1987. Relative efficacy of trimethoprim-sulfamethoxazole and nalidixic acid for acute invasive diarrhoea. Antimicrob. Agent Chemother. 31, 837.
17. Bhattacharya, S.K., M.K. Bhattacharya, P. Dutta, D. Sen, R. Rasaily, A. Moitra, and S.C. Pal. 1991. Randomized clinical trial of norfloxacin for shigellosis. Am. J. Trop. Med. Hyg. 45, 683-687.
18. Bhattacharya, S.K., M.K. Bhattacharya, D. Dutta, S. Dutta, M. Deb, A. Deb, K.P. Das, H. Koley, and G.B. Nair. 1997. Double blind, randomized clinical trial for safety and efficacy of norfloxacin for shigellosis in children. Acta Paediatr. 86, 319-320.
19. Bhattacharya, S.K., and D. Sur. 2003. An evaluation of current shigellosis treatment. Expert Opin. Pharmacothe. 4(8), 1315-1320.
20. Bhattacharya, S.K., K. Sarkar, G.B. Nair, A.S.G Faruque, and D.A. Sack. 2003 A regional alert of multidrug-resistant Shigella dysenteriae type 1 in South Asia. The Lancet. Inf. Dis. 3, 751.
21. Black, R.E, K.H. Brown, S. Becker, A.R. Alim, and I. Huq. 1982. Longitudinal studies of infectious diseases and physical growth of children in rural Bangladesh. II. Incidence of diarrhoea and association with known pathogen. Am. J. Epidemiol. 115, 315-324.
22. Bose, R., J.N. Nashipuri, P.K. Sen, P. Dutta, S.K. Bhattacharya, D. Dutta, D. Sen, and M.K. Bhattacharya. 1984. Epidemic of dysentery in West Bengal: clinicians enigma. Lancet. 2, 1160.
23. Butler, T., P. Speelman, I. Kabir, and J. Banwell. 1986. Colonic dysfunction during shigellosis. J. Infect. Dis. 154, 817-824.
24. Chakrabarti, M.K., J. Bhattacharya, M.K. Bhattacharya, G.B. Nair, S.K. Bhattacharya, and D. Mahalanabis. 1999. Killed oral Shigella vaccine made from Shigella flexneri 2a protects against challenge in the rabbit model of shigellosis. Acta Paediatr. 88, 161-165.
25. Cohen, D., M.S. Green, C. Block, R. Slepon, and Y. Lerman. 1992. Natural immunity to shigellosis in two groups with different previous risks of exposure to Shigella is only partly expressed by serum antibodies to lipopolysaccharide. J. Infect. Dis. 165, 785-787.
26. Cohen, D., S. Ashkenazi, M.S. Green, M. Gdalevich, G. Robin, R. Slepon, M. Yavzori, N. Orr, C. Block, I. Ashkenazi, J. Shemer, D.N. Taylor, T.L. Hale, J.C. Sadoff, D. Pavliakova, R. Schneerson, and J.B. Robbins. 1997. Double-blind vaccine-controlled randomized efficacy trial of an investigational Shigella sonnei conjugate vaccine in young adults. Lancet. 349, 155-159.
27. Conradi, H. 1903. Uber losliche, durch aseptische autolyse erhaltene giftstoffe von ruhrund typhus bazillen. Dtsch. Med. Wochenschr. 20, 26-28.
28. Coster, T.S., C.W. Hoge, L.L. Van DeVerg, A.B. Hartman, E.V. Oaks, M.M. Venkatesan, D. Cohen, G. Robin, A.F. Thompson, P.J. Sansonetti, and T.L. Hale. 1999. Vaccination against shigellosis with attenuated Shigella flexneri 2a strain SC602. Infect. Immun. 67, 3437-3443.
29. Dorman, C.J. and M.E. Porter. 1998. The Shigella virulence regulatory cascade: a paradigm bacterial gene control mechanism. Mol. Microbiol. 29, 677-684.
30. Drusin, L.M. G. Genvert, B. Topf-Olstein, and E. Levy-Zombeck. 1976. Shigellosis: Another sexually transmitted disease? Br. J. Vener. Dis. 52, 348-350.
31. DuPont, H.L., R.B. Hornick, A.T. Dawkins, M.J. Snyder, and S.B. Formal. 1969. The response of man to virulent Shigella flexneri 2a. J. Infect. Dis. 119, 296-299.
32. Du Pont, H.L., M.M. Levine, R.B. Hornick, and S.B Formal. 1989. Inoculum size in shigellosis and implications for expected mode of transmission J. Infect. Dis. 159, 1126-1128.
33. DuPont, H.L., C.D. Ericsson, J.J. Mathewson, E. Palazzini, M.W. DuPont, Z.D. Jiang, A. Mosavi, and F.J. de la Cabada 1998. Rifaximin, a nonabsorbed antimicrobial, in the therapy of travelers diarrhoea. Digestion. 59, 708-714.
34. Ferreccio, C., V. Prado, A. Ojeda, M. Cayyazo, P. Abrego, L. Guers, and M.M. Levine. 1991. Epidemiologic patterns of acute diarrhoea and endemic Shigella infections in a poor periurban setting in Santiago, Chile. Am. J. Epidemiol. 134, 614-627.
35. Finch, M., G. Rodey, D. Lawrence, and P. Blake. 1986. Epidemic Reiters syndrome following an outbreak of shigellosis. Eur. J. Epidemiol. 2, 26-30.
36. Finlay, B.B. and S.Falkow. 1997. Common themes in microbial pathogenecity revisited. Microbiol. Mol. Biol. Rev. 61, 136-169.
37. Flexner, S. 1900. On the etiology of tropical dysentery. Bull. Johns Hopkins Hosp. 11, 231-242.
38. Fontaine, A., J. Arondel, and P.J. Sansonetti. 1988. Role of Shiga toxin in the pathogenesis of bacillary dysentery studied using a tox mutant of Shigella dysenteriae type 1. Infect. Immun. 56, 3099-3109.
39. Formal, S.B., R.M. Maenza, S. Austin, and E.H. LaBrec. 1967. Failure of parenteral vaccine to protect monkeys against experimental shigellosis. Proc. Soc. Exp. Biol. Med. 125, 347-349.
40. Gangarosa, E.J., D.R. Perera, L.J. Mata, C.M. Morris, G. Guzman, and L.B. Reller. 1970. Epidemic Shiga bacillus dysentery in Central America. II. Epidemiologic studies in 1969. J. Infect. Dis. 122, 181-190.
41. Gendrel, D. and F. Moulin. 2001. Fluoroquinolones in paediatrics. Paediatr. Drugs. 3(5), 365-377.
42. Gotuzzo, E., R.A. Oberhelman, C. Maguina, S.J. Berry, A. Yi, M. Guzman, R. Ruiz, R. Leon-Barua, and B. Sack. 1989. Comparison of single-dose treatment with norfloxacin and standard 5-day treatment with trimethoprim- sulphamethoxazole for acute shigellosis in adults. Antimicrob. Agents Chemother. 33, 1101-1104.
43. Guan, S. and N.K. Verma. 1998. Serotype conversion of a Shigella flexneri candidate vaccine strain via a novel site-specific chromosome-intigration system. FEMS Microbiol. Lett. 166, 79-87.
44. Hartman, A.B. and M.M. Venkatesan. 1998. Construction of a stable attenuated Shigella sonnei Delta virG vaccine strain, WRSS1, and protective efficacy and immunogenecity in the guinea pig keratoconjunctivitis model. Infect. Immun. 66, 4572-4576.
45. Hale, T.L. 1991. Genetic basis of virulence in Shigella species. Microbiol. Rev. 55, 206-224.
46. Herrington, D.A., L. Van DeVerg, S.B. Formal, T.L. Hale, B.D. Tall, S.J. Cryz, E.C. Tramont, and M.M. Levine. 1990. Studies in volunteers to evaluate candidate Shigella vaccine: further experience with a bivalent Salmonella typhi-Shigella sonnei vaccine and protection conferred by previous Shigella sonnei disease. Vaccine 8, 353-357.
47. Hong, M., M. Gleason, E.E. Wyckoff, and S.M. Payne. 1998. Identification of two Shigella flexneri chromosomal loci involved in intercellular spreading. Infect. Immun. 66, 4700-4710.
48. Keusch, G.T. 1998. The rediscovery of Shiga toxin and its role in clinical disease. Jpn. J. Med. Sci. Biol. 51(Suppl. I), S5-S22.
49. Khan, W.A., C. Seas, U. Dhar, M.A. Salam, and M.L. Bennish. 1997. Treatment of shigellosis: V. Comparison of azithromycin and ciprofloxacin. A double-blind randomized controlled trial. Ann. Intern. Med. 126(9), 697-703.
50. Kitasato, S. 1894. The bacillus of bubonic plague. Lancet. 2, 428-430.
51. Koster, F., J. Levin, L. Walker, K.S. Tung, R.H. Gilman, M.M. Rahaman, M.M. Majid, S. Islam, and R.C. Williams. 1978. Hemolytic-uremic syndrome after shigellosis. Relation to endotoxemia and circulating immune complexes. N. Eng. J. Med. 298, 927-933.
52. Kotloff, K.L., J.P. Nataro, G.A. Losonsky, S.S. Wasserman, T.L. Hale, D.N. Taylor, J.C. Sadoff, and M.M. Levine. 1995. A modified Shigella volunteer challenge model in which the inoculum is administered with bicarbonate buffer: clinical experience and implications for Shigella infectivity. Vaccine. 13, 1488-1494.
53. Kotloff, K.L., J.P. Winickoff, B. Ivanoff, J.D. Clemens, D.L. Swerdlow, P.J. Sansonetti, G.K. Adak, and M.M. Levine. 1999. Global burden of Shigella infection:Implications for vaccine development and implementation of control strategies. Bull. WHO. 77, 651-666.
54. Kotloff, K.L., F.R. Noriega, T. Samandari, M.B. Sztein, G.A. Losonsky, J.P. Nataro, W.D. Picking, E.M. Barry, and M.M. Levine. 2000. Shigella flexneri 2a strain CVD 1207, with specific deletions in, virG, sen, set, and gua BA, is highly attenuated in humans. Infect. Immun. 68, 1034-1039.
55. Kristjansson, M., B. Viner, and J.N. Maslow. 1994. Polymicrobial and recurrent bacteremia with in a patient with AIDS. Scand. J. Infect. Dis. 26, 411-416.
56. Kruse, W. 1900. Ueberdie Ruhr als Volkskrankheit und ihrer erreger. Dtsch. Med. Wochenschr. 26, 637-639.
57. Levine, M.M., H.L. DuPont, S.B. Formal, R.B. Hornick, A. Takeuchi, E.J. Gangarosa, M.J. Snyder, and J.P. Libonati. 1973. Pathogenesis of Shigella dysenteriae 1 (Shiga) dysentery. J. Infect. Dis. 127, 261-270.
58. Levine, M.M. 1986. Antimicrobial therapy for infectious diarrhoea. Rev. Infect. Dis. 8, S207-S216.
59. Levine, M.M. 1991. Shigellosis. In: Strickland GT, Hunters Tropical Medicine. 7th Edition. Philadelphia, WB Saunders Co., 340-344.
60. Levine, O.S. and M.M. Levine. 1991. House flies (Musca domestica) as mechanical vectors of shigellosis. Rev. Infect. Dis. 13, 688-696.
61. Mata, L.J., E.J. Gangarosa, A. Caceres, D.R. Perera, and M.L. Mejicanos. 1970. Epidemic Shiga bacillus dysentery in Central America, etiologic investigations in Guatemala, 1969. J. Infect. Dis. 122, 170-180.
62. Mathan, V.I. and M.M. Mathan. 1991. Intestinal manifestations of invasive diarrhoeas and their diagnosis. Rev. Infect. Dis. 13 (Suppl 4), S311-313.
63. McCormack, B.A., A.M. Siber, and A.T. Maurerelli. 1998. Requirement of the Shigella flexneri virulent plasmid in the ability to induce trafficking of neutrophils across polarized monolayers of the intestinal epithelium. Infect. Immun. 66, 4237-4243.
64. McKee, K.T. Jr, T.M. Shields, P.R. Jenkins, J.M. Zenilman, and G. E. Glass. 2000. Application of a geographic information system to the tracing and control of an outbreak of shigellosis. Clin. Inf. Dis. 31, 728-733.
65. Mounier, J., V. Laurent, A. Hall, P. Fort, M.F. Carlier, P.J. Sansonetti, and C. Egile. 1999. Rho family GTPases control entry of Shigella flexneri into epithelial cells but not intracellular motility. J. Cell Sci. 112, 2069-2080.
66. Munshi, M.H., D.A. Sack, K. Halder, Z.U. Ahmed, M.M. Rahaman, and M.O. Murshed. 1987. Plasmid-mediated resistance to nalidixic acid in Shigella dysenteriae type 1. Lancet. 2, 419-421.
67. Murphy, G., L. Bodhidatta, P. Echeverria, S. Tansuphaswadikul, C.W. Hoge, S. Imlarp, and K. Tamura. 1993. Ciprofloxacin and loperamide in the treatment of bacillary dysentery. Ann. Intern. Med 118, 582.
68. Nataro, J.P., J. Seriwatana, A. Fasano, D.R. Maneval, L.D. Guers, F. Noriega, F. Dubovsky, M.M. Levine, and J.G. Morris, Jr. 1995. Identification and cloning of a novel plasmid-encoded enterotoxin of enteroinvasive Escherichia coli and Shigella strains. Infect. Immun. 63, 4721-4728.
69. National Committee for Clinical Laboratory Standards. 1997. Performance standard antimicrobial disk susceptibility tests: approved standards. M2-A6, 6th ed. National Committee for Clinical Laboratory Standards, Wayne, Pa.
70. Nelson, J.D., H. Kusmiesz, and L.H. Jackson. 1976. Comparison of trimethoprim/ sulphamethoxazole and ampicillin therapy for shigellosis in ambulatory patients. J. Pediatr. 89, 491.
71. Noriega, F.R., F.M. Liao, S.B. Formal, A. Fasano, and M.M. Levine. 1995. Prevalence of Shigella enterotoxin 1 among Shigella clinical isolates of diverse serotypes. J. Infect. Dis. 172, 1408-1410.
72. Noriega, F.R., Losonsky, G., Lauderbaugh, C., Liao, F.M. Wang, J.Y., and M.M. Levine. 1996. Engineered guaB-A virG Shigella flexneri 2a strain CVD 1205: construction, safety,immunogenecity, and potential efficacy as a mucosal vaccine. Infect. Immun. 64, 3055-3061.
73. Niyogi, S.K., U. Mitra, and P. Dutta. 2001. Changing pattern of serotypes and antimicrobial susceptibilities of Shigella species isolated from children in Calcutta, India. Jpn. J. Infect. Dis. 54, 121-122.
74. Niyogi, S.K., M. Vargas, and J. Vila. 2004. Prevalence of the sat,set and sen genes among diverse serotypes of Shigella flexneri strains isolated from patients with acute diarrhoea. Clin. Microbiol. Infect. 10, 574-576.
75. Nhieu, G.T. and P.J. Sansonetti. 1999. Mechanism of Shigella entry into epithelial cells. Curr. Opin. Microbiol. 2, 51-56.
76. Obituary. The New York Times 1957 26 Jan. sec. 19, 6.
77. Olsson-Liljequist, B. 1992. E-test as a routine MIC tool for reference work. Diagn. Microbiol. Infect. Dis. 15, 479-482.
78. Pal, S.C. 1984. Epidemic bacillary dysentery in West Bengal. Lancet. 1, 1462.
79. Panhotra, B.R., B. Desai, and P.L. Sharma. 1985. Nalidixic acid resistant Shigella dysenteriae type 1. Lancet. 1, 763.
80. Pozsgay, V., C. Chiayung, L. Pannel, J. Wolfe, J.B. Robbins, and R. Schneerson. 1999. Protein conjugates of synthetic saccharides elicit higher levels of serum IgG lipopolysaccharide antibodies in mice than do those of the O-specific polysaccharide from Shigella dysenteriae type 1. Proc. Natl. Acad. Sci. USA 96, 5194-5197.
81. Rahaman, M.M., M.M. Khan, K.M.S. Aziz, M.S. Islam, and A.K. Kibriya. 1975. An outbreak of dysentery caused by Shigella dysenteriae type 1 on a coral island in the bay of Bengal. J. Infect. Dis. 13215.
82. Robbins, J.B, C.Y. Chu, and R. Schneerson. 1992. Hypothesis for vaccine development : Protective immunity to enteric diseases caused by non-typhoidal Salmonella and Shigellae may be conferred by serum IgG antibodies to the O-specific polysaccharide of their lipopolysaccharides. Clin. Infect. Dis. 15, 346-361.
83. Robbins, J.B, R. Schneerson, and S.C. Szu. 1995. Perspective: hypothesis: serum IgG antibody is sufficient to confer protection against infectious disease by inactivating the inoculum. J. Infect. Dis. 171, 1378-1398.
84. Ross, S., G. Controno, and W. Khan. 1972. Resistance of shigellae to ampicillin and other antibiotic. J. Am. Med. Assoc. 221, 45.
85. Sack, R.B., M. Rahman, M. Yunus, and E.H. Khan. 1997 Antimicrobial resistance in organisms causing diarrhoeal disease. Clin. Infect. Dis. 24(suppl. 1), S102-105.
86. Salam, M.A. and M.L. Bennish. 1988. Therapy for shigellosis I randomized double-blind trial of nalidixic acid in childhood shigellosis. J. Pediatr. 113, 901-907.
87. Salam, M.A. and M.L. Bennish. 1991. Antimicrobial therapy for shigellosis. Rev. Infect. Dis. 13(Suppl 4), S332-S341.
88. Salam, M.A., C. Seas, W.A. Khan, and M.L. Bennish. 1995. Treatment of shigellosis: IV cefixime is ineffective in shigellosis in adults. Am. Intern. Med. 123(7), 505-508.
89. Sansonetti, P.J. and J. Arondel. 1989. Construction and evaluation of a double mutant of Shigella flexneri as a candidate for oral vaccination against shigellosis. Vaccine 7, 443-450.
90. Sansonetti, P.J. and C. Egile. 1998. Molecular bases of epithelial cell invasion by Shigella flexneri? Antonie Van Leeewenhoek. 74, 191-197.
91. Sarkar, K., S. Ghosh, S.K. Niyogi, and S.K. Bhattacharya. 2003. Shigella dysenteriae type 1 with reduced susceptibility to fluoroquinolone. Lancet. 361, 785.
92. Schuch, R. and A.T. Maurelli. 1999. The mxi-Spa type III secretory pathway of Shigella flexneri requires an outer membrane lipoprotein MxiM, for invasion translocation. Infect. Immun. 67, 1982-1991.
93. Sen, D., P. Dutta, B.C. Deb, and S.C. Pal. 1988. Nalidixic acid resistant Shigella dysenteriae type 1 in Eastern India. Lancet. 2, 911.
94. Shears, P. 1996. Shigella infection. Ann. Trop. Med. Parasitol. 90, 105-114.
95. Shiga, K. 1898. Ueber den Erreger der Dysenterie in Japan. Vorlaufige Mitteilung Zentralbal Bakteriol Microbiol Hyg. 23, 599-600.
96. Shiga, K. 1898. Ueber den Dysenterie bacillus (Bacillus dysenteriae), Zentralbl Bakteriol Parasitenkd Abt I Org. 24, 817-824.
97. Shiga, K. 1906. Obsevation on the epidemiology of dysentery in Japan. Philippine J. of Sci. 1, 485-500.
98. Shiga, K. and K. Kanwa. 1950. Tokyo: Nihon Iji Shimpo Shuppanbu.
99. Shiga, K. 1936. The trend of prevention, therapy, and epidemiology of dysentery since the discovery of its causative organisms. N. Engl. J. Med. 215, 1205-1211.
100. Sieper, J., J. Braun, P. Wu, R. Hauer, and S. Laitko. 1993. The possible role of Shigella in sporadic enteric reactive arthritis. Br. J. Rheumatol. 32, 582-585.
101. Struelens, M.J., D. Patte, I. Kabir, A. Salam, S.K. Nath, and T. Butler. 1985. Shigella septicemia: prevalence, presentation, risk factors, and outcome. J. Infect. Dis. 152, 784-790.
102. Sur, D., S.K. Niyogi, S. Sur, K.K. Datta, Y. Takeda, G.B. Nair, and S.K. Bhattacharya 2003. Multi-drug resistant Shigelaa dysenteriae type 1: Forerunners of a new epidemic strain in eastern India? Emerg. Inf. Dis. 9(3), 404-405.
103. Taylor, D., P. Echeverria, T. Pal, O. Sethabutr, S. Saiborisuth, S. Sricharmorn, B. Rowe, and J. Cross. 1986. The role of Shigella spp., enteroinvasive Escherichia coli and other enteropathogens as cause of childhood dysentery in Thailand. J. Infect. Dis. 153, 1132-1138.
104. Todd, C. 1904. On a dysentery toxin and antitoxin. J. Hyg. 4, 480-494.
105. Trofa, A.F., H. Ueno-Olsen, R. Oiwa, and M. Yoshikawa. 1999. Dr. Kiyoshi Shiga: Discoverer of the dysentery bacillus. Clin. Infect. Dis. 29, 1303-1306.
106. Vargas, M., J. Gascon, M.T. Jimenez, De Anta., and J. Vila. 1999. Prevalence of Shigella enterotoxins 1 and 2 among Shigella strains isolated from patients with travelers diarrhoea. J. Clin. Microbiol. 37, 3608-3611.
107. Varsano, I., T. Elditz-marcus, M. Nussinovch, and I. Elian. 1991. Comparative efficacy of ceftriaxone and ampicillin for treatment of severe shigellosis in children. J. Pediatr. 118, 627-632.
108. Venkatesan, M., P.C. Fernandez, J.M. Buysee, S.B. Formal, and T.L. Hale. 1991. Virulence phenotype and genetic characteristics of the T32-1STRATI Shigella flexneri 2a vaccine strain. Vaccine 9, 358-363.
109. Way, S.S., A.C. Borczuk, R. Dominit, and M.B. Goldberg. 1998. An essential role for gamma interferon in inate resistance to Shigella flexneri infection. Infect. Immun. 66, 1342-1348.
110. Way, S.S. and M.B. Goldberg. 1998. Clearance of Shigella flexneri occurs through a nitric oxide independent mechanism. Infect. Immun. 66, 3012-3016.
111. World Health Organization. 1987. Manual for the investigation of acute enteric infections, programme for control of diarrhoeal diseases. Geneva CDD/83.3. Rev. 1.
112. World Health Organization. 1995. The treatment of diarrhoea. A manual for physicians and other senior health workers. Geneva, Switzerland (WHO/CDR/95.3).
113. World Health Organization. 1997. New strategies for accelerating Shigella vaccine development. Weekly Epidemiol Record. 72, 73-80.
114. World Health Organization. 2001. Antimicrobial resistance in shigellosis, cholera and campylobacteriosis.WHO/CDS/CSR/DRS/2001.8. World Health Organization, Geneva, Switzerland.
115. Yavzori, M., D. Cohen, and N. Orr. 2002. Prevalence of the genes for shigella enterotoxin 1 and 2 among clinical isolates of shigella in Israel. Epidemiol. Infect. 128, 533-535.